Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 12 systematic review(s)/meta-analysis(es). ^[1-12]
• Cenobamate demonstrated statistically significant higher responder rates (≥50% and 100%) and seizure freedom compared to other new-generation antiseizure medications (ASMs), particularly eslicarbazepine, indicating its superior effectiveness.
• Eslicarbazepine acetate showed a significant ≥50% reduction in seizure frequency, with evidence suggesting increasing efficacy with higher doses, although it was less effective than cenobamate.
• Moderate-certainty evidence indicates that eslicarbazepine may reduce seizure frequency in children aged 6 to 18 years, though the results remain inconclusive.
• Cenobamate was identified as a valuable treatment option for patients with drug-resistant epilepsy, particularly in achieving higher responder rates and improving quality of life compared to third-generation ASMs.
• Eslicarbazepine was associated with treatment-emergent adverse events (TEAEs) such as dizziness, nausea, somnolence, diplopia, and vomiting, and demonstrated a lower patient retention rate compared to placebo.
• Cenobamate exhibited comparable TEAE withdrawal rates to other ASMs, while it had a higher probability of experiencing at least one TEAE compared to some other ASMs, though the differences were not statistically significant.
• Eslicarbazepine showed a higher incidence of serious adverse events and adverse event-related withdrawals compared to placebo, with specific adverse events including vestibulocerebellar symptoms, hyponatremia, and rash, particularly at higher doses.
• Eslicarbazepine may reduce seizure frequency in children aged 6 to 18 years, although the evidence remains inconclusive, while cenobamate is identified as a valuable treatment option for drug-resistant epilepsy (DRE) in adults, showing high efficacy compared to third-generation antiseizure medications.